Fertin Pharma A/S
VEJLE, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fertin Pharma A/S (“Fertin Pharma
”) has signed and closed the acquisition of Tab Labs Inc. (“Tab Labs
”), a leader in compressed gum and mints / lozenges and one of the largest contracts tableting companies in North America servicing customers within Nutraceuticals as well as Confectionery.
Headquartered in Vejle, Denmark, Fertin Pharma is the leading independent B2B developer and manufacturer of medical chewing gum, primarily within Nicotine Replacement Therapy (“NRT ”), a pharmaceutical product used for withdrawal management in the process of tobacco cessation. Furthermore, Fertin Pharma has a wide portfolio of other medicated chewing gum products as well as Nutraceutical products. In recent years the company’s unparalleled expertise within chewing gum has been further expanded with a range of lozenges and products based on the innovative Zapliq® platform1 .
Tablabs will serve as an important bridgehead for Fertin Pharma in the large North American market for dietary supplement products delivered through innovative and convenient systems such as chewing gum, mints, lozenges and Zapliq®. Based in Vancouver, Canada, Tab Labs will also provide MedCan Pharma A/S, an affiliate of Fertin Pharma, with an interesting opportunity to serve the Canadian market with edible types of Cannabinoid containing products. A market that is expected to be liberalised within the next 12 months and is estimated to be a market reaching a value of more than a billion dollars in 2023.
If you want to learn more about Fertin Pharma and explore opportunities for collaboration, please visit www.fertin.com . In case of questions related to the acquisition of Tab Labs, please contact Søren Birn, CEO, Claudio Bidco A/S and Fertin Pharma A/S on +45 7215 1521.
1
Zapliq® is an innovative, patented delivery system invented by Fertin Pharma. Zapliq® is unique in its ability to transform from a solid dose format into a liquid in seconds. Zapliq® allows for high convenience, potentially faster on-set of action and interesting taste masking capabilities. Zapliq® can be used as a delivery system for both Rx, OTC and Nutraceutical products.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Financière de Tubize SA2.8.2025 08:00:00 CEST | Press release
Financière de Tubize - 2025 half-year financial report
DBV Technologies S.A.1.8.2025 22:05:00 CEST | Press release
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
Mandalay Resources Corporation1.8.2025 21:12:01 CEST | Press release
Mandalay Obtains Final Order Approving Arrangement with Alkane
F. Hoffmann-La Roche Ltd1.8.2025 20:00:00 CEST | Press release
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
KBC Groep1.8.2025 18:10:00 CEST | Press release
KBC Group: KBC remains well-capitalised under 2025 EU-wide EBA stress test
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom